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Objectives: To assess the association between hyperuricemia and different neuropsychiatric
manifestations and stroke risk factors in systematic lupus erythematosus (SLE) patients.
Methods: This study was conducted on 204 SLE patients who were admitted to a tertiary
referral center. A standardized questionnaire was completed for all the participants and
the  medical records were reviewed regarding the occurrence of arterial or venous throm-
botic  events, stroke, seizure, depression, headache, psychosis, and peripheral neuropathy.
In  addition blood samples were drawn to obtain serum uric acid, triglyceride (TG), high-
density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and total
cholesterol levels.
Results: Hyperuricemia (serum uric acid ≥6 mg/dl for women and ≥7 mg/dl for men) was
detected in 16.1% of SLE patients and was signiﬁcantly associated with the occurrence of
stroke (OR, 2.38; 95%CI, 1.2–7.24), and peripheral neuropathy (OR, 3.49; 95% CI, 1.52–12.23),
independent of hypertension and hyperlipidemia. Hyperuricemia was also signiﬁcantly
associated with hypertension (OR, 7.76; 95% CI, 2.72–15.76), hyperlipidemia (OR, 5.05; 95%
CI,  1.59–11.32), and history of arterial thrombosis (OR, 4.95; 95% CI, 1.98–15.34), independent
of  age and body mass index.
Conclusions: Hyperuricemia in SLE patients is independently associated with the occurrence
of  stroke and peripheral neuropathy. It is also independently associated with hyperten-
sion,  hyperlipidemia, and history of arterial thrombosis, which are the major stroke andmyocardial infarction risk factors in SLE patients.
© 2015 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Hiperuricemia  no  lúpus  eritematoso  sistêmico:  está  associada  a
manifestac¸ões  neuropsiquiátricas  da  doenc¸a?
Palavras-chave:
Neurologia
Neuropatia
Lúpus eritematoso sistêmico
Acidente vascular encefálico
Ácido úrico
r  e  s  u  m  o
Objetivos: Avaliar a associac¸ão entre a hiperuricemia e diferentes manifestac¸ões neurop-
siquiátricas e os fatores de risco para AVE em pacientes com lúpus eritematoso sistêmico
(LES).
Métodos: Este estudo foi realizado em 204 pacientes com LES que foram internados em
um centro de referência de atenc¸ão terciária. Todos os participantes preencheram um
questionário padronizado e os prontuários médicos foram analisados quanto à ocorrên-
cia  de eventos trombóticos arteriais ou venosos, acidente vascular encefálico, convulsão,
depressão, cefaleia, psicose e neuropatia periférica. Além disso, foram coletadas amostras
de  sangue para se mensurar os níveis de ácido úrico, triglicerídeos (TG), lipoproteínas de
alta  densidade (HDL), lipoproteínas de baixa densidade (LDL) e colesterol total do sangue.
Resultados: A hiperuricemia (ácido úrico sérico ≥6 mg/dl para mulheres e ≥7 mg/dl para
homens) foi detectada em 16,1% dos pacientes com LES e esteve signiﬁcativamente asso-
ciada à ocorrência de AVE (OR, 2,38; IC 95%, 1,2–7,24) e neuropatia periférica (OR, 3,49; IC
95%, 1,52–12,23), independentemente da hipertensão arterial e da hiperlipidemia. A hipe-
ruricemia também esteve signiﬁcativamente associada à hipertensão arterial (OR, 7,76; IC
95%,  2,72–15,76), hiperlipidemia (OR, 5,05; IC 95%, 1,59–11,32) e história de trombose arterial
(OR, 4,95; 95% CI, 1,98–15,34), independentemente da idade e índice de massa corporal.
Conclusões: A hiperuricemia em pacientes com LES está independentemente associada à
ocorrência de acidente vascular encefálico e neuropatia periférica. Também está indepen-
dentemente associada à hipertensão, hiperlipidemia e história de trombose arterial, que são
os  principais fatores de risco para acidente vascular encefálico e infarto agudo do miocárdio
em  pacientes com LES.
© 2015 Elsevier Editora Ltda. Este e´ um artigo Open Access sob uma licenc¸a CCIntroduction
Uric acid, the ﬁnal product of purine degradation, is formed in
the liver from precursor proteins and is excreted by the kid-
neys and intestines. At physiologic concentrations, uric acid
exhibits excellent antioxidant activity; however, when uric
acid exceeds its physiologic levels, it can propagate oxidative
damage. Furthermore, chronic elevation of uric acid con-
stitutes a risk factor for many  diseases, as it can promote
inﬂammation and endothelial dysfunction.1,2
Hyperuricemia is a risk factor for myocardial infarction
and stroke.3 In addition higher serum urate levels after acute
stroke is a predictor of poor outcome and higher rates of
future vascular event.4 Hyperuricemia has been also asso-
ciated with peripheral neuropathy in diabetes.5 Therefore
some researchers recommended lowering plasma uric acid
levels to reduce the risk of future vascular events in high risk
populations.4,6
Neurologic involvement and vascular events have a wide
range of frequency (12–95%) in patients with systemic lupus
erythematosus (SLE) and can be very common causing signif-
icant morbidity and mortality in SLE patients.7 Based on the
studies that showed higher levels of uric acid in SLE patients,8,9
and the studies that documented the injurious effect of uric
acid on the nervous system,6 we  postulate that hyperuricemia
in SLE patients might increase the risk of neurologic involve-
ment and vascular events during the course of the disease. By
our extensive search we could not ﬁnd studies assessing theBY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
relation between serum uric acid levels and the different neu-
ropsychiatric manifestations of SLE. Whether a high serum
uric acid level in SLE patients constitutes a risk factor for future
neurologic, psychiatric and vascular involvements, remains
unknown. Identifying these associations is very important and
might help in identifying a modiﬁable risk factor for the neu-
rologic and vascular events in SLE patients.
We undertook this study to evaluate the effect of hyper-
uricemia on the different neurologic manifestations seen in
SLE patients; we  also attempted assessing the associations of
serum uric acid levels with the patients’ blood pressure and
lipid proﬁle, and the occurrence of vascular and thrombotic
events.
Materials  and  methods
Study  population  and  study  design
This study was conducted on SLE patients who were admit-
ted at our center (a tertiary referral hospital) between March
2011 and February 2014. A total of 235 SLE patients who  met
the American College of Rheumatology (ACR) SLE criteria par-
ticipated in the study,10 and 31 of these were excluded due
to the following criteria: history of smoking; opiate or alco-
hol consumption; and history of infections, fever, or antibiotic
use during the previous two weeks. After obtaining a written
informed consent, a total of 204 SLE patients aged 18–54 years
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Table 1 – Demographic characteristics and some laboratory markers of the participants with and without hyperuricemia.
The characteristic Hyperuricemia p value
Yes (n = 33) No (n = 171)
Age (years) (Mean ± SD) 37.6 ± 13.2 34.7 ± 10.9 0.2
Disease Duration (years) (Mean ± SD) 6.3 ± 4 6 ± 4 0.8
BMI (Mean ± SD) 25.1 ± 5 25.7 ± 4.8 0.5
Male Gender [Number (%)] 9 (27.3%) 31 (18.1%) 0.1
Serum CRP (Mean ± SD) 8.7 ± 15 9 ± 31.7 0.9
ESR (Mean ± SD) 42 ± 36.7 28.8 ± 26.2 0.05
Positive ANA [Number (%)] 26 (78.7%) 123 (71.9%) 0.2
Positive Anti ds-DNA [Number (%)] 23 (69.6%) 97 (56.7%) 0.1
SD, standard deviation; CRP, c-reactive protein; ESR, erythrocyte sedimentation rate; ANA, anti nuclear antibody; Anti ds-DNA, anti double
c
m
D
U
p
r
c
w
t
ﬁ
r
e
d
s
w
e
d
a
(
u
u
(
l
a
m
o
n
S
A
s
a
w
w
b
u
p
l
e
d
≥90 mmHg  or being treated with hypertensive drugs), 43
(21%) had hyperlipidemia (deﬁned as serum total cholesterol
≥240 mg/dl, LDL cholesterol ≥160 mg/dl, or TG ≥200 mg/dl),12
Table 2 – The drugs used by the participants with
and without hyperuricemia.
The drug Hyperuricemia p value
Yes (n = 33) No (n = 171)
Prednisolone 33 (100%) 166 (97%) 0.4
Hydroxychloroquine 16 (48.4%) 102 (59.6%) 0.1
Cellcept 13 (39.3%) 57 (33.3%) 0.3
Azathioprine 7 (21.2%) 48 (28%) 0.2strand DNA.
ompleted the study, which was approved by the ethics com-
ittee and the research deputy of our institute.
ata  and  specimen  collection
pon enrollment a standardized questionnaire was com-
leted for every participant through interviews, medical
ecords, and physical examinations. The questionnaire
onsisted of demographic, medical, and social histories, as
ell as inquiries about body mass index (BMI), disease dura-
ion, and the received treatments and their duration. Patients
les were investigated and the following information were
ecorded: the occurrence of arterial or venous thrombotic
vents documented by imaging studies, occurrence of stroke
ocumented by imaging studies, recent onset seizure demon-
trated by an abnormal electroencephalography (EEG) that
as not due to infection or metabolic disturbances, the pres-
nce of depression, headache, psychosis due to lupus as
eﬁned by the ACR and SLE disease activity index (SLEDAI),10,11
nd peripheral neuropathy documented by electromyography
EMG) and nerve conduction velocity (NCV) studies. In addition
pon enrollment blood samples were drawn to obtain serum
ric acid, creatinine, blood urea nitrogen (BUN), triglyceride
TG), high-density lipoprotein (HDL) cholesterol, low-density
ipoprotein (LDL) cholesterol, and total cholesterol levels. Uric
cid levels were determined by the enzymatic colorimetric
ethod, and all laboratory investigations were performed by
ne person who  was blinded to the results of the question-
aires.
tatistical  analysis
ll statistical analyses were performed using SPSS statistical
oftware (version 18.0.0:  PASW,  Chicago, IL). The Chi-square
nalysis, Fisher’s exact test, independent samples t-test, one-
ay analysis of variance, and Pearson correlation analysis
ere used to analyze the correlations and relationships
etween the variables. Multivariate logistic regression was
sed to evaluate the dependency of the obtained results. Sam-
le size was calculated for an alpha error of 0.05, a desired
evel of absolute precision (d) of 0.05, and an estimated design
ffect (DEFF) of one. Estimated odds ratios (OR) with 95% conﬁ-
ence intervals (95% CI) and p values were used to evaluate thestatistical signiﬁcance of the associations and correlations
between the variables.
Results
Descriptive  statistics
A total of 235 SLE patients agreed to participate in the study;
of these, 31 patients were excluded. Sixteen of the 31 excluded
patients had a history of smoking and opiate or alcohol con-
sumption, and 15 had infections or had used antibiotics during
the previous two weeks. The remaining 204 SLE patients
completed the study. At enrollment, the population charac-
teristics expressed as mean ± standard deviation (SD) were as
follows: participants’ age, 35.3 ± 11.4 years; disease duration,
6 ± 4 years; BMI, 25.6 ± 4; serum creatinine, 0.9 ± 0.4 mg/dl;
BUN, 20.4 ± 9.2 mg/dl; and serum uric acid, 4.7 ± 1.5 mg/dl.
No signiﬁcant differences were observed in the demo-
graphics of the SLE patients with and without hyper-
uricemia (Table 1). There were no signiﬁcant differences
between the drugs used by the participants in each group
(Table 2).
Of the participants who completed the study, 40 (19.6%)
were male, 69 (33.8%) had hypertension (deﬁned as sys-
tolic blood pressure ≥140 mmHg  or diastolic blood pressureAspirin 3 (9%) 20 (11.6%) 0.4
Statins 4 (12.1%) 26 (15.2%) 0.4
Calcium 7 (21.2%) 64 (37.4%) 0.05
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Table 3 – Association between hyperuricemia and different neuropsychiatric manifestations of SLE.
Neurologic manifestations of SLE Hyperuricemia Unadjusted OR
(95% CI)
Adjusted ORa
(95% CI)
Yes (n = 33) No (n = 171)
N (%) N (%)
CVA (n = 19) 8  (24.2%) 11 (6.4%)b 4.65 (1.7–12.69) 2.38 (1.2–7.24)
Seizure (n = 22) 5 (15.1%) 17 (9.9%) 1.61 (0.55–4.74) 1.4 (0.45–7.7)
Headache (n = 55) 16 (48.5%) 39 (22.8%)c 3.18 (1.47–6.88) 2.74 (0.98–9.88)
Peripheral neuropathy (n = 12) 6 (18.2%) 6 (3.5%)b 6.11 (1.83–20.34) 3.49 (1.52–12.23)
Psychosis (n = 10) 4 (12.1%) 6 (3.5%)c 3.79 (1–14.27) 3.32 (0.9–16.11)
Depression (n = 23) 5 (15.2%) 18 (10.5%) 1.51 (0.52–4.42) 1.1 (0.35–5.64)
SLE, systemic lupus erythematosus; OR, odds ratio; 95% CI, 95% conﬁdence interval; CVA, cerebrovascular accident.
a Adjusted for hypertension and hyperlipidemia.
b p < 0.05 for the comparison between two groups with and without hyperuricemia after performing logistic regression.
t hypc p < 0.05 for the comparison between two groups with and withou
22 (10.7%) had experienced at least one seizure attack, 10 (4.9%)
had psychosis, 23 (11.27%) had depression, 55 (26.9%) had a
severe headache, 19 (9.3%) had experienced CVA, 12 (5.8%) had
peripheral neuropathy, 50 (24.5%) had experienced at least one
venous thrombosis formation, and 20 (9.8%) had experienced
at least one arterial thrombus formation.
The  association  between  hyperuricemia  and  the  different
neurologic  manifestations  of  SLE
Hyperuricemia was deﬁned as serum uric acid ≥6 mg/dl for
women and serum uric acid ≥7 mg/dl for men.13 Hyper-
uricemia was detected in 33 SLE patients (16.1%) and was
signiﬁcantly associated with the occurrence of CVA (p = 0.001),
psychosis (p = 0.03), peripheral neuropathy (p = 0.001), and
headache (p = 0.003). There was no statistically signiﬁcant
association between hyperuricemia and seizures (p = 0.3) or
depression (p = 0.4) (Table 3).
The  associations  between  serum  uric  acid  levels  and  the
different  known  CVA  risk  factors
Based on the Pearson correlation coefﬁcients, serum uric
acid levels were signiﬁcantly correlated with blood pressure
(r = 0.5, p = 0.000), total cholesterol (r = 0.3, p = 0.000), TG (r = 0.03,
p = 0.000), and LDL cholesterol (r = 0.2, p = 0.004). We did not ﬁnd
a statistically signiﬁcant correlation between serum uric acid
Table 4 – Association between hyperuricemia and different kno
Factors Hyperuricemia 
Yes (n = 33) No (
N (%) N
Hypertension (n = 69) 25 (75.8%) 44 (2
Hyperlipidemia (n = 43) 17 (51.5%) 26 (1
Hx of arterial thrombosis (n = 20) 9 (27.3%) 11 (6
Hx of venous thrombosis (n = 50) 10 (30.3%) 40 (2
OR, odds ratio; 95% CI, 95% conﬁdence interval; CVA, cerebrovascular acci
a Adjusted for age and body mass index (BMI).
b p < 0.05 for the comparison between two groups with and without hyperuricemia.
levels and the participants’ age, BMI, or HDL cholesterol level.
Hyperuricemia was associated with hypertension (p = 0.000),
hyperlipidemia (p = 0.000), and arterial thrombosis (p = 0.000),
while there was no signiﬁcant association between hyper-
uricemia and venous thrombosis (p = 0.3) (Table 4).
Dependency  of  the  obtained  results
Using multivariate logistic regression, after adjustment for
hypertension and hyperlipidemia, hyperuricemia remained
signiﬁcantly associated with CVA (B = 0.87, p = 0.04) and
peripheral neuropathy (B = 1.25, p = 0.04) but not with
psychosis (B = 1.2, p = 0.1) or headache (B = 1.01, p = 0.05)
(Table 3).
After adjustment for age and BMI, hyperuricemia remained
signiﬁcantly associated with hypertension (B = 2.05, p = 0.000),
hyperlipidemia (B = 1.62, p = 0.006), and arterial thrombosis
(B = 1.6, p = 0.001) (Table 4).
Discussion
Hyperuricemia  and  SLEIn the current study, hyperuricemia was detected in 16.1% of
SLE patients (22% in men  and 16.4% in women), which was
higher than the prevalence of hyperuricemia in the normal
wn risk factors of CVA.
Unadjusted OR
(95% CI)
Adjusted ORa
(95% CI)
n = 171)
 (%)
5.7%)b 9.02 (3.79–21.46) 7.76 (2.72–15.76)
5.2%)b 5.92 (2.66–13.19) 5.05 (1.59–11.32)
.4%)b 5.45 (2.04–14.53) 4.95 (1.98–15.34)
3.4%) 1.42 (0.62–3.24) 1.22 (0.54–5.67)
dent; Hx, history.
eruricemia.
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opulation, as reported by studies conducted in the same
egion using the same cutoff points.14 This is in accordance
ith other studies that showed higher levels of uric acid
mong SLE patients.8,9 Higher prevalence of hyperuricemia in
LE patients might be due to several endogenous and exoge-
ous mechanisms such as inﬂammation, hypertension, and
enal involvement, which are prevalent in SLE patients and
ave been identiﬁed as provoking hyperuricemia through dif-
erent mechanisms.15–19 On the other hand, increased levels
f uric acid can aggravate inﬂammation, hypertension, and
enal disease,15–19 thus creating a vicious cycle. Hyperactivity
f the xanthine oxidase enzyme in SLE patients,8 and some of
he drugs used in the treatment of SLE,20 are among the other
ossible reasons for the higher prevalence of hyperuricemia
n SLE patients.
yperuricemia  and  hyperlipidemia
n our study, the serum uric acid level was signiﬁcantly cor-
elated with the serum TG, LDL, and total cholesterol levels,
nd hyperuricemia was signiﬁcantly associated with hyper-
ipidemia, independent of age and BMI. These ﬁndings are in
ccordance with other studies that involved both human and
nimal models.21,22 Hyperuricemia appears to have a mutual
nteraction with high serum TG and cholesterol levels, thus
orming a vicious cycle, whereas some studies have shown
hat lipids and hypertriglyceridemia increase serum uric acid
evels through increasing its absorption in the renal tubules
nd also through increasing uric acid production by accel-
rating the de novo purine synthesis.23 Other studies have
ocumented that uric acid might have a contributory role in
ncreasing serum TG, LDL, and total cholesterol levels. Naka-
awa et al., in their study of the effect of uric acid on metabolic
yndrome, documented that lowering uric acid improves
nsulin sensitivity, obesity, and hypertriglyceridemia. They
lso indicated that uric acid might be involved in either the
verproduction or the reduction of TG clearance.21 In another
tudy, Bowden et al. documented that hyperuricemia is asso-
iated with higher total cholesterol, LDL, and apolipoprotein B
Apo B) levels, and a reduction causes a decrease in serum
DL and total cholesterol levels. They indicated that uric
cid is a major cause of oxidative stress and reduced nitrous
xide (NO) release, and combined with an increase in the
ctivity of lipoprotein lipase may cause higher lipid levels
nd particle numbers. Furthermore, hyperuricemia is thought
o impair endothelium-dependent vasodilatation primarily
hrough lipid oxidation, which can cause an increase in the
otal cholesterol level.22
yperuricemia  and  hypertension
n this study of SLE patients, hyperuricemia was signiﬁ-
antly associated with hypertension, independent of age and
MI. Grayson et al. in their meta-analysis of hyperuricemia
nd incident hypertension, which included data from
5,607 patients, found a signiﬁcantly increased adjusted
isk ratio for incident hypertension in subjects with
yperuricemia, independent of traditional risk factors for
ypertension.15 It is now believed that hyperuricemia has a
ausative role in hypertension through different mechanisms; 6;5 6(6):471–477 475
uric acid activates the renin–angiotensin system and down-
regulates nitric oxide (NO) production, thus leading to
vasoconstriction. Another effect of uric acid, which devel-
ops overtime, is uric acid mediated arteriolosclerosis; uric
acid uptake into vascular smooth muscle cells causes the
activation and production of growth factors and monocyte
chemoattractant protein-1, which results in vascular smooth
muscle cell proliferation, vascular wall thickening, loss of vas-
cular compliance, and a shift in pressure natriuresis.1,2,15–17
Hyperuricemia,  hypercoagulability  state,  and  CVA
In the current study, hyperuricemia was signiﬁcantly associ-
ated with CVA in SLE patients, independent of hypertension
and hyperlipidemia. This is in accordance with other stud-
ies conducted in general populations. A recently published
12–15 years prospective study by Storhaug et al. that included
5700 participants without known risk factors for cardiovas-
cular diseases documented that a 1 SD (1.47 mg/dl) increase
in serum uric acid was signiﬁcantly associated with a 22%
increased risk for ischemic stroke and 13% increased risk
for all-cause mortality.24 Additionally, in our study, hyper-
uricemia was independently associated with a history of at
least one arterial thrombosis event. These important ﬁndings
suggest that hyperuricemia might increase the risk for CVA
not only by increasing the risk for developing hyperlipidemia
and hypertension as mentioned earlier, but also through other
mechanisms; hyperuricemia has been associated with platelet
activation and increased platelet adhesiveness.25,26 Thus,
patients with hyperuricemia might have an increased risk
of thrombus formation. In addition, hyperuricemia has been
associated with the progression of atherosclerosis through the
promotion of oxygenation of LDL cholesterol and facilitation of
lipid peroxidation.3,4,6 Furthermore, hyperuricemia can cause
endothelial dysfunction and reduce NO production leading to
an impaired vascular tone that could contribute to ischemic
changes.1,2,15,24
Hyperuricemia  and  peripheral  neuropathy
In our study, hyperuricemia was signiﬁcantly associated with
peripheral neuropathy in SLE patients, independent of hyper-
tension and hyperlipidemia. This important ﬁnding suggests
that hyperuricemia might have an injurious effect on the
peripheral nervous system. Similar results were found in dia-
betic patients. Papanas et al., in their study of 64 diabetic
patients, detected a signiﬁcant correlation between serum
uric acid and the neuropathy disability score. They also
indicated that diabetic patients with peripheral neuropathy
had increased serum uric acid levels compared to levels in
those without neuropathy.5 The exact role of uric acid in
peripheral neuropathy remains unknown; however, uric acid
might play a role in peripheral neuropathy through its role
in oxidative damage and vascular endothelial dysfunction.
Studies have shown that when uric acid exceeds its physio-
logic value in the plasma, it can propagate oxidative damage
and cause oxidative stress,1,2,22 which has been shown to
induce neuronal damage; oxidative stress is the central
mediator of apoptosis, neuro-inﬂammation, and bioenergetic
failure in neurons.27 In addition, hyperuricemia promotes
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inﬂammation and endothelial dysfunction, and reduces NO
production and bioavailability.1,2,15 Endothelial dysfunction
and low levels of NO may lead to constriction of blood
vessels supplying the nerve, which contributes to nerve
damage.28
Conclusion
Hyperuricemia is prevalent among SLE patients and is sig-
niﬁcantly associated with CVA and peripheral neuropathy in
SLE patients. It is also signiﬁcantly associated with hyper-
tension, hyperlipidemia, and a positive history for arterial
thrombosis, which are the major CVA and myocardial infarc-
tion risk factors. Follow up studies are needed to measure
serum uric acid at the beginning and through the course
of the disease to evaluate the effect of hyperuricemia on
the progression of neuropsychiatric manifestations of SLE
and its morbidity through the course of the disease. Addi-
tionally interventional studies are needed to determine the
practical usefulness of lowering serum uric acid levels in SLE
patients.
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